Fig. 5: Performance evaluation of the AI model in the prospective study.
From: Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial
a–d, The performance of effectiveness (a), safety (b), overall acceptability (c) and adoption rate of AI-generated regimen (d) evaluated by endocrinologists at the bedside at test–retest review in the prospective study (n = 40 regimens). The score scale of effectiveness and safety is 1–5. The adoption rate refers to the percentage of the AI regimens adopted by endocrinologists at the bedside for patient treatment. Bar graphs depict the mean ± s.e.m.
